Organization | University of Winnipeg

University of Winnipeg Report issue

Academic/Hospital Phase 2 Phase 4

Founded: Winnipeg MB Canada (1871)

Organization Overview

First Clinical Trial

2003

NCT00156819

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Health Sciences Centre, Winnipeg, Manitoba

Active Ingredients

Drugs in Phase 4 Trials (3)

fluticasone (cutivate) (1 trial)

montelukast (singulair) (2 trials)

salmeterol (serevent) (1 trial)

Drugs in Phase 2 Trials (2)

budesonide (rhinocort) (1 trial)

indomethacin (indocin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Asthma (Phase 4)

Bronchopulmonary Dysplasia (Phase 2)

Ductus Arteriosus, Patent (Phase 2)

Premature Birth (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 4
# of Trial APIs: 5